Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
The anti-CD52 (Campath-1) monoclonal antibodies (Mabs) have a substantial history of use for controlling graft-versus-host disease in allogeneic bone marrow transplantation. Now, with the availability of a humanised form, alemtuzumab (Campath-1H), and the demonstration that this agent can reduce the...
Main Authors: | Hale, G, Slavin, S, Goldman, J, Mackinnon, S, Giralt, S, Waldmann, H |
---|---|
פורמט: | Journal article |
שפה: | English |
יצא לאור: |
2002
|
פריטים דומים
-
In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation.
מאת: Kottaridis, P, et al.
יצא לאור: (2001) -
Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype.
מאת: Dyer, M, et al.
יצא לאור: (1989) -
REMISSION INDUCTION IN PATIENTS WITH LYMPHOID MALIGNANCIES USING UNCONJUGATED CAMPATH-1 MONOCLONAL-ANTIBODIES
מאת: Dyer, M, et al.
יצא לאור: (1990) -
In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.
מאת: Kottaridis, P, et al.
יצא לאור: (2000) -
Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up.
מאת: Clatworthy, MR, et al.
יצא לאור: (2009)